In Situ Hybridization Market Size Is Poised To Reach $2.42 Billion By 2030: Grand View Research Inc.

 

San Francisco, 31 July 2023: The Report In Situ Hybridization Market Size, Share & Trends Analysis Report By Technology, By Probe, By Product, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

The global in situ hybridization market size is expected to reach USD 2.42 billion by 2030 and is set to expand at 6.9% CAGR from 2023 - 2030, according to a new report by Grand View Research, Inc. Situ Hybridization (ISH) is extensively utilized for research and clinical applications of diagnostics. ISH is a popular approach among researchers as it aids in determining the relationship between the distribution of specific nucleic acids and the target gene protein products. Hence, expanding the scope of ISH in applications is accelerating and leading to further research.

The increasing awareness about ISH techniques and their usage encourages researchers to employ the techniques for various applications. For instance, the CEO of MultiplexDX stated in an interview with Elsevier that FISH technology can contribute breakthrough information for early drug development and personalized treatment. A growing number of people in developed countries are opting for personalized treatment owing to an increase in awareness, thus boosting market demand.

Furthermore, reimbursement schemes being made available in developed economies have led to an increase in demand for this diagnosis. The demand continues to increase as the majority of the public can now afford it due to the recent expansion through insurance coverage. For instance, Medicare is the largest market player in the U.S., which provides care for those aged 65 years and above, irrespective of their income and medical history.

Owing to the COVID-19 pandemic, the demand side showcased a positive impact on the ISH market as various researchers employed the technique on COVID-19-infected cells. Research published in July 2020, considered 8 autopsy lungs, 10 kidney biopsies, and 1 placenta from COVID-19-infected patients with ISH assay and RNA probes.

COVID-19 positive results showed in all 8 lungs and the placenta by ISH, but not in the kidney samples. The assay showcases a sensitive and specific technique for detecting the virus from tissue samples. Similarly, Advanced Cell Diagnostics, Inc., introduced RNAscope technology to support COVID-19 research.

The growing strategic initiatives by the companies are anticipated to boost the ISH market growth. Key players are introducing novel products in the market to strengthen their portfolios. For instance, in March 2021, F. Hoffmann-La Roche launched DISCOVERY Green HRP chromogen detection kit to expand the multiplexing capability of in situ hybridization and immunohistochemistry.

On the other hand, molecular diagnostics renders accurate & effective results and has indispensable applications in the field of diagnosis. However, the high manufacturing cost of FISH assays and the high amount of capital required for specialized assembly plants & maintenance of instruments used in FISH imaging are likely to limit revenue generation.

Request sample report of In Situ Hybridization Market@ https://www.grandviewresearch.com/industry-analysis/in-situ-hybridization-ish-market/request/rs1

In-situ hybridization has become an important process to identify, localize, and detect the specific DNA sequences in cells with an increasing number of unknown viruses, such as COVID-19.  Growing demand for molecular diagnostic tools is anticipated to boost the adoption of In Situ Hybridization (ISH) technology in the coming years. The rising prevalence of chronic diseases coupled with the increasing need for rapid diagnostic techniques contributes to the increased adoption of ISH.

In Situ Hybridization Market Report Highlights

• By technology, the CISH segment is projected to expand at the fastest growth rate during the forecast period. Since the reagents used in CISH are more stable, the sample can be stored for a longer duration and can be examined multiple times
• By probe, the DNA segment is anticipated to have the fastest growth rate during the forecast period. Owing to the increasing incidence of diseases associated with chromosomal aberrations, such as genetic abnormalities and cancer
• By product, the services segment is anticipated to have the fastest-growing CAGR between 2023 to 2030. Increasing outsourcing to ensure high adherence to quality standards and improve operational functionalities contributes to the lucrative growth

The In Situ Hybridization (ISH) industry is predominantly driven by technological advancements in the field of IVD. The advent of 3D FISH technology is one of the major advancements responsible for lucrative growth opportunities. It facilitates visualization and analysis of target cells in 3D aspects, thereby creating the potential for optimal research outcomes.

In Situ Hybridization Market Report Scope 

Report Attribute	Details
Market size value in 2023	USD 1.51 billion
Revenue forecast in 2030	USD 2.42 billion
Growth rate	CAGR of 6.9% from 2023 to 2030
Base year for estimation	2022
Historical data	2018 - 2021
Forecast period	2023 - 2030

List of Key Players in the In-Situ Hybridization Market

• Thermo Fisher Scientific Inc.
• Abbott (Abbott Molecular)
• PerkinElmer, Inc.
• BioView
• Agilent Technologies, Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Oxford Gene Technology IP Limited
• Leica Biosystems Nussloch GmbH
• F. Hoffman-La Roche Limited
• NeoGenomics Laboratories, Inc.
• Advanced Cell Diagnostics, Inc.

Access Press Release of In Situ Hybridization Market@ https://www.grandviewresearch.com/press-release/global-in-situ-hybridization-ish-market